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Abstract 
Arterial thrombosis is the primary cause of most cases of myocardial infarction and 
stroke, the leading causes of death in the developed world. Platelets, highly specialized 
cells of the circulatory system, are key contributors to thrombotic events. Antiplatelet 
drugs, which prevent platelets from aggregating, have been very effective in reducing the 
mortality and morbidity of these conditions. However, approved antiplatelet therapies 
have adverse side effects, most notably the increased risk of bleeding. Moreover, there 
remains a considerable incidence of arterial thrombosis in a subset of patients receiving 
currently available drugs. Thus, there is a pressing medical need for novel antiplatelet 
agents with a more favorable safety profile and less patient resistance. The discovery of 
novel antiplatelet targets is the matter of intense ongoing research. Recent findings 
demonstrate the potential of targeting key signaling molecules, including kinases and 
phosphatases, to prevent platelet activation and aggregation. Here, we offer perspectives 
to targeting members of the protein tyrosine phosphatase (PTP) superfamily, a major 
class of enzymes in signal transduction. We give an overview of previously identified 
PTPs in platelet signaling, and discuss their potential as antiplatelet drug targets. We also 
introduce VHR (DUSP3), a PTP that we recently identified as a major player in platelet 
biology and thrombosis. We review our data on genetic deletion as well as 
pharmacological inhibition of VHR, providing proof-of-principle for a novel and 
potentially safer VHR-based antiplatelet therapy. 
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1. Introduction 
 Circulating platelets play a crucial role in hemostasis, acting to maintain the integrity of 
a closed circulatory system after blood vessel injury.
2
 They are recruited to the site of 
vascular damage, where they adhere to the exposed subendothelial matrix and become a 
major component of the developing thrombus that seals the breach. Under normal 
conditions, regulatory mechanisms restrain thrombus formation both temporally and 
spatially. When pathologic processes overwhelm the regulatory mechanisms of 
hemostasis, excessive quantities of thrombin are formed, initiating thrombosis.
1, 2
 
Thrombosis can occur in the arterial or the venous circulation and has a major medical 
impact.
3
 Venous thromboembolism is the third leading cause of cardiovascular-associated 
death. Acute arterial thrombosis is the primary cause of most cases of myocardial 
infarction and stroke, collectively the most common causes of death in the developed 
world.
4
  
Available antiplatelet therapies are used for both the prevention and the acute treatment 
of arterial thrombosis. These drugs target either one of the three major processes leading 
to platelet activation and thrombus formation: 1) the initial phase of platelet recruitment 
and adhesion to the vessel wall, 2) the platelet aggregation phase, and 3) the stabilization 
of platelet aggregates during the amplification phase (Fig. 1). Aspirin has been used 
clinically for more than 40 years and is the most commonly used antiplatelet drug.
5, 6
 It 
inhibits cyclooxygenase-1, which is required for the synthesis of thromboxane A2 (TXA2), 
a secondary mediator of platelet aggregation. Thienopyridines, including clopidogrel, 
ticlopidine, and prasugrel, are irreversible inhibitors of the P2Y12 ADP receptor and also 
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widely used as antiplatelet drugs.
7, 8
 In fact, clopidogrel (Plavix) is one of the best selling 
drugs of all time, with peak sales of $9.3 billion in 2011 (source: FirstWord Pharma). 
Both, aspirin and clopidogrel inhibit the formation of stable platelet aggregates. More 
recently developed amplification phase inhibitors include ticagrelor,
9
 a P2Y12 receptor 
antagonist, vorapaxar
10, 11
 and atopaxar,
12
 which are antagonists of the thrombin-activated 
G-protein coupled receptor (GPCR) PAR-1, and dipyridamole and cilostazol,
13
 both 
phosphodiesterase 3 (PDE3) selective inhibitors that increase cAMP levels and block 
platelet responses to ADP. Investigational drugs include the TXA2 receptor antagonists 
terutroban and EV-077.
14, 15
 Platelet aggregation phase inhibitors in clinical use include 
the monoclonal antibody abciximab, the cyclic heptapeptide eptifibatide, and the small 
molecule tirofiban.
16
 These drugs all inhibit the interaction between glycoprotein IIb/IIIa 
(also known as integrin IIb3) and fibrinogen, thereby potently inhibiting platelet 
aggregation. At present, there are no drugs in clinical use that block the initial recruitment 
and binding of platelets to adhesive
 
macromolecules of the subendothelial matrix, such as 
collagen or von Willebrand factor (vWF). Molecules in clinical studies that inhibit the 
interaction between vWF and glycoprotein (GP) Ib on the surface of platelets include the 
aptamer ARC-1779,
17
 the monoclonal antibody caplacizumab,
18
 and the snake venom-
derived C-type lectin-like protein anfibatide.
19
 Collagen receptor GPVI inhibitors in 
development include compounds that induce depletion of GPVI, antibodies that bind to 
GPVI, and soluble GPVI mimetics that bind to collagen.
20
  
Antiplatelet therapy has been very effective in reducing the mortality and morbidity of 
acute myocardial infarction and stroke.
4
 However, approved antiplatelet agents have 
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adverse side effects, including gastrointestinal toxicity, neutropenia, thrombocytopenia, 
and bleeding.
4
 Moreover, there remains a considerable incidence of arterial thrombosis in 
patients resistant to currently available antiplatelet therapy. For example, the delayed 
onset of action and the occurrence of poor platelet inhibition responders with clopidogrel 
is well documented.
4
 Thus, despite the great success of antiplatelet therapy, there is an 
unmet medical need for novel antiplatelet agents with a more favorable safety profile, 
better efficacy in certain patient groups, and rapid onset and offset of action in acute 
events. Efforts in the pharmaceutical industry have focused on developing new-
generation drugs of well-established targets, including the P2Y12 ADP receptor, the PAR-
1 thrombin receptor, and the TXA2 receptor.
4
 In addition, the discovery of novel targets is 
the matter of intense ongoing research. Recently, various kinases have emerged as 
promising antiplatelet targets. Proof-of-principle studies have been reported for 
phosphatidylinositol 3-kinase (PI3K) isoform p110,21, 22 the non-receptor spleen 
tyrosine kinase (Syk),
23, 24
 and Src family kinases (SFKs).
25, 26
 These findings 
demonstrate the possibility of targeting key regulators of platelet receptor signaling 
pathways as novel antiplatelet strategies.  
Tyrosine phosphorylation is an important mechanism of signal transduction,
27, 28
 
including in platelets,
29, 30
 as it crucially activates or inhibits the function of signaling 
molecules. For instance, tyrosine phosphorylation can result in conformational changes of 
the tertiary or quaternary structure of proteins, thereby rapidly amplifying or attenuating 
the catalytic activity of enzymes.
31
 It also promotes crucial protein-protein interactions, 
e.g., the recruitment and activation of signaling molecules to the cytoplasmatic tail of 
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cell-surface receptors. Tyrosine phosphorylation is a rapidly reversible post-translational 
modification, controlled by the opposing activities of protein tyrosine kinases (PTKs) and 
protein tyrosine phosphatases (PTPs).
27, 28
 Historically, research had long been focused 
on the role PTKs in signaling and disease, as it was generally believed that PTPs 
functioned merely as indiscriminate ‘housekeeping’ enzymes with broad specificities. 
However, we now appreciate that PTPs are not only as numerous and diverse as PTKs, 
we have also started to understand how highly specific these enzymes indeed act on their 
substrates in vivo, and how tightly regulated they are to maintain homeostasis.
32-36
 Indeed, 
the rapidly increasing number of disorders associated with PTP abnormalities has begun 
to elicit a growing interest in these enzymes as drug targets, including in major diseases 
such as cancer,
37, 38
 diabetes,
39
 autoimmunity,
40, 41
 and Alzheimer’s.42 While PTPs have 
been well studied in numerous cell types, in particular in cells of the immune system,
40, 43, 
44
 the expression, regulation, specificity, and function of PTPs in platelets are largely 
unknown. Recent proteomic analyses found that 20 out of the 37 classical, 
phosphotyrosine (pTyr)-specific PTPs are expressed in human platelets.
45
 Only four of 
them had been previously identified as critical regulators of platelet function. Platelet 
expression and function of the 63 dual-specificity phosphatases (DSPs),
32, 34
 the largest 
subgroup of PTPs, had been entirely unexplored. A summary of PTPs reported in platelet 
function is presented in Table 1.  
Our laboratories recently published work investigating the role of DSPs in human 
platelets, implicating the Vaccinia H1-related (VHR) phosphatase (also known as DUSP3) 
as a key positive regulator of platelet signaling through the GPVI collagen receptor and 
the C-type lectin-like 2 (CLEC-2) podoplanin receptor.
46
 More importantly, we found that 
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VHR-deficient mice were more resistant to collagen- and epinephrine-induced 
thromboembolism, compared to wild-type (WT) mice, and showed severely impaired 
thrombus formation upon FeCl3-induced carotid artery injury.
46
 Intriguingly, bleeding 
times were not altered in VHR-deficient mice. To investigate VHR function in human 
platelets, we developed a specific small-molecule inhibitor of VHR. This compound 
specifically inhibited GPVI- and CLEC-2-induced human platelet aggregation, thereby 
phenocopying the effect of VHR deficiency in murine cells. This was the first time a 
specific platelet PTP had been targeted with a small-molecule drug. Our findings, which 
we discuss in more detail in Section 3 of this perspective article, may lead to a novel, 
effective, and safer antiplatelet therapy. 
 
2. Classical PTPs in platelet signaling 
Four classical PTPs have been identified as critical regulators of platelet function, 
namely: the transmembrane receptor-like PTP CD148 and the intracellular non-receptor 
like PTPs PTP1B, SHP1, and SHP2. Below we discuss the main functions of these PTPs 
in platelet reactivity, as well as their potential as antithrombotic drug targets.  
2.1. CD148 (PTPRJ, DEP-1): Master regulator of platelet reactivity 
CD148 is a fundamental regulator of platelet reactivity (Fig. 2).
47
 Platelets rely heavily 
on CD148 function to regulate SFK activity and signaling from immunoreceptor 
tyrosine-based activation motif (ITAM)-containing receptors and integrins.
48, 49
 CD148 
consists of a large, highly glycosylated ectodomain (containing eight fibronectin type III 
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domains), a single transmembrane domain, and a single PTP domain in its cytoplasmic 
tail. Physiologically relevant ligands of CD148 remain ambiguous, although syndecan-2 
and thrombospondin-1 were recently reported to bind CD148.
50, 51
 The C-terminal 
inhibitory tyrosine residue of SFKs is the most well established substrate of CD148. 
However, CD148 also attenuates SFK activity by dephosphorylating the activation loop 
tyrosine residue, thus acting as a molecular rheostat, optimizing SFK activity under 
resting and activated conditions.
49
 
Targeted deletion of CD148 in mice has profound consequences on platelet reactivity and 
thrombosis due to a dramatic reduction in SFK activity both in resting and activated 
platelets.
47
 The capacity of CD148 to attenuate SFK activity is masked in CD148-
deficient mice, where the net effect is a reduction in platelet reactivity. CD148-deficient 
platelets exhibit impaired responses to collagen and fibrinogen.
47
 However, responses to 
thrombin and TXA2 are only marginally impaired, while responses to ADP are normal. 
Thrombus formation is markedly reduced in CD148 constitutive knockout mice, 
following laser- and FeCl3-induced injury of arterioles, with a minor prolongation of 
bleeding. CD148-deficient platelets also exhibit a concomitant 50% reduction in GPVI 
expression, which contributes to the reduced reactivity to collagen.
47
 These findings 
clearly establish CD148 as a critical positive regulator of platelet activation and 
aggregation.  
CD148 expression is tightly regulated in human platelets, in which little inter-individual 
variability is observed.
47
 Specific polymorphisms identified in the extracellular region of 
CD148 (Q276R and R326Q) have a protective effect in the development of heparin-
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induced thrombocytopenia by reducing platelet reactivity to antibody-platelet factor 
4/heparin complexes, which activate platelets via clustering of the ITAM-containing Fc- 
receptor IIA (FcRIIA).52 It is proposed that these mutations introduce torsional stress 
and a loss of positive charge in the second fibronectin type III domain of CD148 that may 
affect ligand binding or membrane compartmentalization of CD148.
52
 Collectively, these 
findings suggest CD148 as a potential antiplatelet drug target.  
Because CD148 not only regulates the basal level of SFK activity, but also the threshold 
of signaling from a number of platelet receptors (Fig. 2), we anticipate that inhibiting 
CD148 is likely to have dramatic effects on thrombus formation. Thus, we believe it 
would be an appropriate target in the most severe thrombotic cases, such as disseminated 
intravascular coagulation or post-operatively, when thrombus formation is a high risk. As 
with all antiplatelet therapies, bleeding side effects are a distinct possibility, which may 
be minimized by titrating the dose of a reversible inhibitor. The ectodomain of CD148 is 
an obvious target, owing to the ease of access. Blocking ligand binding would 
presumably alter the threshold of platelet activation. Indeed, a monoclonal antibody 
targeting the extracellular domain of CD148 has been shown to inhibit CD148-dependent 
endothelial cell growth and angiogenesis in mouse cornea, providing proof-of-principle 
of this strategy.
53
 The cytoplasmatic juxtamembrane region, PTP domain, and C-terminal 
tail region are also potential targets, with the added challenge of the drug needing to cross 
the plasma membrane. Currently, no CD148-specific inhibitors are available. 
2.2. PTP1B (PTPN1): Positive regulator of outside-in integrin signaling 
PTP1B is highly expressed in platelets and is a positive regulator of outside-in signaling 
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from the integrin IIb3.
54, 55
 Specifically, PTP1B dephosphorylates the C-terminal 
inhibitory tyrosine of 3-associated SFKs, initiating downstream signaling (Fig. 3).55, 56 
Outside-in signaling regulates cytoskeletal remodeling and is essential for platelet 
spreading on fibrinogen, as well as clot retraction, two essential processes for stable 
thrombus formation and cessation of bleeding. Interestingly, mice lacking PTP1B have 
normal platelet counts and show no apparent bleeding tendency, suggesting that PTP1B 
is dispensable for primary hemostasis.
55
 However, they exhibit a dramatic reduction in 
thrombus formation following laser-induced injury of arterioles. Whether or not the 
reduced thrombus formation is due exclusively to the absence of PTP1B in platelets has 
yet to be elucidated. PTP1B-deficient platelets exhibit reduced spreading on fibrinogen,
55, 
57
 yet they bind soluble fibrinogen and aggregate normally in response to the GPVI 
agonists collagen-related peptide (CRP) and convulxin, the P2Y12 and P2Y1 agonist ADP, 
and the PAR-4 agonist thrombin.
55, 57
 In line with these observations, PTP1B-deficient 
platelets aggregate normally on collagen under intermediate shear conditions, but 
aggregate volume is dramatically reduced at high shear conditions (3,000 s
-1
), typically 
found in stenotic arteries prone to occlusion.
57
 This provides further compelling evidence 
for PTP1B as a potential anti-thrombotic target. The highly specific role of PTP1B in 
platelets may in fact make it a better target than the more globally acting CD148, 
predicting fewer bleeding side effects compared to inhibiting CD148.  
PTP1B has been considered a potential drug target in the treatment of type 2 diabetes 
since its role as a negative regulator of insulin receptor signaling was published some 15 
years ago.
58
 More recently, PTP1B has also been implicated in the development of 
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breast
59, 60
 and prostate
61
 cancer. Despite a tremendous effort put into the development of 
specific PTP1B inhibitors, both in academia and industry, only a few compounds 
progressed to clinical trials, and none have advanced beyond phase II (Table 2).
62-65
 This 
is largely due to the conventional approach taken to target the highly conserved PTP1B 
active site.
32
 However, novel strategies of inhibiting PTP1B have emerged, including the 
use of cell-permeable antisense oligonucleotides (ISIS-PTP1BRX, ISIS Pharmaceuticals), 
as well as the development of inhibitors that target less conserved, allosteric sites in 
PTP1B (e.g., trodusquemine, Table 2).
66, 67
 These novel and promising approaches may 
result in the first PTP1B inhibitors with clinical potential. Importantly, targeting PTP1B 
may have secondary health benefits in conditions such as diabetes and cancer where 
thrombosis is a known consequence. 
2.3. SHP1 (PTPN6) and SHP2 (PTPN11): Critical regulators of platelet homeostasis 
The closely related Src homology 2 (SH2) domain-containing phosphatases SHP1 and 
SHP2 use their tandem N-terminal SH2 domains to bind to immunoreceptor tyrosine-
based inhibition motifs (ITIMs) associate with the platelet endothelial cell adhesion 
molecule 1 (PECAM-1), which functions as a negative regulator of platelet reactivity and 
thrombosis,
68
 but has also been implicated as a positive regulator of the outside-in 
signaling properties of IIb3.
69
 PECAM-1-mediated membrane localization of SHP1 and 
SHP2 is thought to allow them to access and dephosphorylate key signaling and 
cytoskeletal molecules. Work done using SHP1 and SHP2 conditional knockout mice 
revealed complex phenotypes that are not compatible with a simple model of SHP1 and 
SHP2 solely acting as negative regulators of platelet signaling.
70
 Table 1 and Figure 4 
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highlight putative functions attributed to SHP1 and SHP2 in platelets and 
megakaryocytes. Mice lacking either SHP1 or SHP2 in the megakaryocyte lineage (i.e., 
in platelets and their progenitors megakaryocytes) exhibited distinct phenotypes that were 
exacerbated in double knockout mice, demonstrating non-redundant functions that 
collectively regulate platelet production and homeostasis. Deletion of both SHP1 and 
SHP2 resulted in a critical block in megakaryocyte development and survival and almost 
a complete absence of platelets in the circulation. As a result, SHP1/2 double knockout 
mice had a severe bleeding diathesis. Interestingly, a similar phenotype was seen in mice 
lacking G6b-B,
70
 an ITIM-containing receptor that was previously shown to be associated 
with SHP1 and SHP2.
71
  
Based on these findings, targeting SHP2 may be beneficial in treating conditions 
characterized by overproduction of platelets such as thrombocythemia or polycythemia 
vera, both myeloproliferative disorders that are frequently caused by elevated signaling 
via the thrombopoietin receptor MPL (also known as myeloproliferative leukemia 
protein). Indeed, SHP2 inhibitors (Table 2) are currently being developed for the 
treatment of various leukemias and other forms of cancer,
72, 73
 where elevated SHP2 
activity contributes to oncogenesis.
74, 75
 In contrast, inhibition of SHP1, for which no 
specific inhibitors have been reported, may result in undesirable side effects, given its 
important negative regulatory role in many survival and growth signaling pathways in 
hematopoietic cells,
43
 and the fact that mice deficient in SHP1 display a severe 
autoimmune and immunodeficiency syndrome (motheaten mouse).
76, 77
 Thus, one of the 
main challenges in targeting SHP2 is to generate inhibitors with sufficient selectivity for 
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SHP2 over its closely related cousin SHP1. 
 
3. VHR (DUSP3): Major positive regulator of platelet signaling and thrombosis 
VHR, first described by Ishibashi et al.,
78
 and named for its sequence similarity with the 
VH1 gene in Vaccinia virus, is a member of the dual-specificity phosphatases. The DSP 
subfamily of PTPs is the most diverse group in terms of substrate specificity, ranging 
from pTyr-specific to phosphothreonine (pThr)/pTyr-specific, to phosphoserine (pSer)-
specific, to pSer/pThr-specific DSPs. Additionally, some DSPs can also dephosphorylate 
mRNA or phosphatidylinositol phosphates.
32, 34
 VHR is a small DSP (185 amino acids; 
20.5 kDa), containing only a catalytic PTP domain, with a preference for 
dephosphorylating pTyr over pSer/pThr.
79
 Reported substrates of VHR in vitro are the 
receptor tyrosine kinases EGFR, KGFR, PDGFR, and the insulin receptor,
78
 as well as 
the MAP kinases ERK1/2 and JNK1/2.
80, 81
 However, dephosphorylation of MAP kinases 
by VHR remains controversial.
46, 82, 83
 Several reports implicated VHR in cell cycle 
regulation and cancer.
84-87
 For instance, RNA interference-mediated knockdown of VHR 
in HeLa cells caused cell cycle arrest at the G1-S and G2-M transitions and also induced 
cell senescence.
84
 In addition, VHR was found upregulated in prostate and cervix 
carcinomas,
86, 87
 and pharmacological inhibition of VHR decreased the proliferation of 
HeLa and other cervix cancer cell lines.
85
 Finally, in the LNCaP prostate cancer cell line, 
androgen-induced VHR expression reduced 12-O-tetradecanoylphorbol-13-acetate- and 
thapsigargin-induced apoptosis.
87
 Based on these reports, VHR behaves like a pro-
oncogene.
88
 However, VHR also acts as a tumor-suppressor in breast cancer
89
 and non-
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small cell lung cancers.
82, 90
 Regardless, the actual biological functions of VHR are still 
poorly understood. (A more detailed survey of the literature can be found in a recent 
review by Pavic et al.
91
) 
3.1. VHR is a key positive regulator of the GPVI and CLEC-2 pathways in platelets 
We recently found that VHR is highly expressed in human and mouse platelets.
46
 We 
previously generated VHR-knockout (VHR-KO) mice
92
 and utilized these animals to 
study the role of VHR in hemostasis and thrombosis.
46
 We found that VHR-KO mice 
were more resistant to pulmonary thromboembolism than their WT littermates. Moreover, 
thrombus formation was strongly impaired after FeCl3-induced injury of carotid arteries 
in a platelet-specific manner. Intriguingly, bleeding was not affected by VHR deficiency, 
suggesting that VHR plays a key role in arterial thrombosis, but is dispensable for 
primary hemostasis.
46
 Ex vivo, VHR deficiency resulted in defective platelet aggregation, 
granule secretion, and integrin IIb3 inside-out activation, specifically in response to 
GPVI and CLEC-2 stimulation (Fig. 5). Platelet activation mediated by GPCRs (i.e., the 
P2Y12, TXA2, and thrombin receptors) was not affected. Impaired thrombus formation in 
VHR-KO mice was comparable to the previously reported GPVI-KO/FcR93-95 
CLEC-2-KO,
96
 CLEC-2-depleted,
97
 GPVI-depleted,
98
 and CLEC-2/GPVI-depleted 
mice.
99
 The finding that VHR-deficient mice show no apparent bleeding tendency was in 
line with what was observed previously in GPVI-KO and CLEC-2-KO mice.
93, 96, 100
 
VHR-KO mice were also protected against pulmonary thromboembolism, similar to 
GPVI-KO mice.
100
  
At the molecular level, phosphorylation of the previously reported VHR substrates 
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ERK1/2 and JNK1/2 was not affected by VHR deficiency in platelets. However, we 
found significantly reduced pTyr levels in the tyrosine kinase Syk, a key signaling 
molecule in GPVI- and CLEC-2-mediated platelet activation (Fig. 5). Upon stimulation, 
Syk phosphorylation was reduced on the activatory residues Tyr-525/526, while 
phosphorylation on Tyr-323, which is implicated in Syk ubiquitination/degradation,
101
 
was not affected. Previous data suggested that Syk is recruited to the GPVI/Fc receptor -
chain (FcR) complex via phosphorylation of FcR-associated ITAMs by SFKs.102, 103 
We found that phosphorylation of FcR-associated ITAMs was reduced, and recruitment 
of Syk to FcR was impaired in VHR-KO compared to WT platelets. Additionally, 
inducible tyrosine phosphorylation in phospholipase-C (PLC) 2, a key signaling 
molecule downstream of Syk, was also reduced in VHR-deficient compared to WT 
platelets. In contrast, phosphorylation of inhibitory or activatory tyrosine residues in 
SFKs, including Lyn, Fyn, and Src, was not altered, indicating that the reduced activation 
and recruitment of Syk in VHR-deficient platelets was not due to aberrant activation of 
SFKs. At this point we do not know the direct target(s) of VHR in platelets. Given that 
VHR deficiency led to a decrease of pTyr in Syk, and no proteins with an increase in 
pTyr could be identified, our data raise the question whether pSer/pThr in Syk, SFKs, or 
other protein(s) may be dephosphorylated by VHR. However, due to the limited usability 
of available pSer/pThr antibodies, future studies using quantitative phospho-proteomics 
will be necessary to address this question. 
3.2. Pharmacological inhibition of VHR in human platelets phenocopies the effect of 
VHR deficiency 
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Platelets derive from cytoplasmatic fragments of megakaryocytes and hence are anucleate 
cells that are not amenable to RNA interference or recombinant DNA technologies. Tool 
compounds to pharmacologically inhibit (or activate) the function of a specific signaling 
molecule in human platelets are invaluable to corroborate findings that originate from 
animal models. In our study, we utilized a chemical genomics approach to develop a 
specific small-molecule inhibitor of VHR (Fig. 6).
46
 High-throughput screening (HTS) of 
~300,000 drug-like molecules (from the NIH Molecular Libraries Program) culminated 
in 67 hits with confirmed activities in two orthogonal PTP assays (colorimetric and 
fluorimetric),
104, 105
 and dose-dependent responses with IC50 values <20 μM. Based on 
compound potency and selectivity (derived from subsequent counter-screens against four 
related PTPs), two scaffolds were selected for structure-activity relationship (SAR) 
studies: MLS-0103602 (IC50 = 0.37 μM) and MLS-0049585 (IC50 = 2.68 μM). Analogs 
of MLS-0103602 included 37 benzothioamide derivatives that were tested against VHR. 
All analogs were at least an order of magnitude less potent than the original hit with no 
improvement of selectivity, leading to the termination of this series. In contrast, several 
analogs of MLS-0049585 with similar or even better potency and selectivity could be 
identified. Testing of these inhibitors on human platelets collected from healthy donors 
revealed an efficient inhibition of platelet aggregation by compound MLS-0437605. This 
effect of MLS-0437605 was specific to platelets activated through the GPVI and CLEC-2 
receptors, equivalent to the effect of VHR deficiency in murine cells. Tests on platelets 
from WT mice yielded similar results, while MLS-0437605 only minimally affected 
aggregation of VHR-deficient platelets. In selectivity profiling studies against a larger 
panel of PTPs, MLS-0437605 showed excellent selectivity for VHR over the vast 
  
 17 
majority of PTPs tested, including good selectivity over VHX (DUSP22), another DSP 
that we found highly expressed in platelets.
46
 Similar to VHR deficiency, inhibition of 
VHR by MLS-0437605 in human platelets reduced tyrosine phosphorylation of 
immunoprecipitated Syk and PLC2 in response to GPVI and CLEC-2 stimulation; 
global tyrosine phosphorylation was not affected. Collectively, our data demonstrate that 
pharmacological inhibition of VHR activity in human platelets phenocopies the effect of 
VHR deficiency in murine platelets. Given that VHR-KO mice remain healthy and do not 
suffer from increased bleeding events, MLS-0437605 may serve as the basis for the 
development of a novel antiplatelet strategy in the treatment of arterial thrombosis.  
 
4. Challenges in targeting PTPs 
PTPs are the largest class of protein phosphatases with over 100 members in humans.
32-36
 
They are defined by their active-site signature motif C(X)5R, which is part of the 
phosphate-binding loop (P-loop) that, together with additional conserved loops, forms the 
catalytic pocket.
32
 PTPs share a common catalytic mechanism that is based on key amino 
acids within these loops, most importantly a nucleophilic cysteine and an invariant 
arginine that are part of the signature motif. The vast majority of reported small-molecule 
PTP inhibitors target the catalytic site. These compounds are usually potent, but poorly 
selective, due to the fact that they often carry a charged pTyr-mimicking group that 
provides most of the binding energy through interactions with the highly conserved P-
loop.
32, 64, 105-110
 High-affinity peptides carrying nonhydrolyzable (fluoro)phosphonate 
group(s) exhibit incredible potency and selectivity, but little to no cell-based activity, 
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owing to their multi-charged nature and poor drug-likeness, resulting in the lack of cell 
membrane permeability.
111
 Peptidic tool compounds that cross cell membranes were 
generated by the addition of long-chain fatty acids
112
 or cell-penetrating peptides such as 
polyarginines.
113
 Additionally, prodrug strategies to deliver charged compounds more 
easily into cells have been utilized.
114-116
 However, generating small-molecule drug-like 
PTP inhibitors with significant selectivity for a particular PTP over related enzymes 
remains challenging. Selectivity of active site inhibitors can be increased by tailoring 
compounds to interact with unique amino acids and surface features peripheral of the 
catalytic pocket, an approach that is supported by large-scale structural analyses of 
PTPs.
117
 Because such compounds are designed to interact with both the catalytic site and 
additional peripheral sites, the trade-off is usually expanded size and molecular weight of 
inhibitors, resulting in lower ligand efficiency,
118
 and compounds that are less likely to 
enter cells or to be absorbed in the gut. Several new approaches to overcome the 
selectivity hurdle have been proposed. These include inhibitors that target a less 
conserved inactive-state PTP conformation, inhibitors that target allosteric sites in PTPs, 
as well as inhibitors that specifically bind a PTP in its oxidized state. (For more 
information on these new approaches please see our recent review article.
32
) Interestingly, 
Michaelis-Menten kinetic studies suggest a noncompetitive inhibition mode for our VHR 
inhibitor MLS-0437605, a compound that lacks any pTyr-mimicking group (unpublished 
data). Noncompetitive inhibition is typical for allosteric inhibitors; however, further 
studies are needed to conclusively determine the mode of action of MLS-0437605. 
Certainly, allosteric inhibition of PTPs has been gaining significant traction recently,
66, 67, 
119, 120
 and further success could result in a major paradigm shift in how we target PTPs in 
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the future. Finally, targeting the extracellular domains of receptor-like PTPs such as 
CD148 has been under-exploited to date, but may provide unique opportunities in terms 
of drug specificity and target accessibility. In a recent study by Takahashi and co-workers, 
antibody-induced cross-linking of CD148 resulted in inhibition of endothelial cell growth 
and angiogenesis.
53
 It is conceivable that a similar approach may inhibit activation of 
platelets. 
 
5. Conclusion 
Antiplatelet therapy has been very successful in the prevention and treatment of arterial 
thrombosis, the primary cause of most cases of myocardial infarction and stroke. 
However, approved antiplatelet drugs have adverse side effects and are not effective in a 
considerable subset of patients. In the search for novel antiplatelet agents with a more 
favorable safety profile and better efficacy, the discovery of new targets is the matter of 
intense research. Protein tyrosine phosphatases are important molecules for receptor 
signal transduction and platelet activation. Previous research implicated CD148, PTP1B, 
SHP1, and SHP2 as critical regulators in platelet signaling. Recent findings from our 
laboratories show that VHR, a dual-specificity phosphatase, plays a selective and 
essential role in GPVI- and CLEC-2-mediated platelet activation and thrombus formation 
in vivo. In contrast to current antiplatelet therapies, which completely inhibit a specific 
receptor or signaling pathway, findings from the CD148, PTP1B, and VHR knockout 
mouse studies suggest that inhibiting a specific PTP can reduce platelet function, but 
not completely abrogate it. Thus, platelets can still respond to all agonists, albeit less 
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strongly, which, in turn, may result in fewer bleeding side effects. However, because 
CD148 is a global regulator of platelet reactivity, inhibition of CD148 is more likely to 
have bleeding consequences than, for instance, targeting PTP1B or VHR. Effective 
targeting of PTPs with drug-like molecules has been very difficult to achieve. 
Specifically, the generation of selective PTP inhibitors remains challenging. However, 
recent developments, in particular in regards to allosteric mechanisms, demonstrate the 
possibility to overcome the selectivity hurdle, which so far has impeded the success of 
PTP inhibitors in the clinic. Our novel VHR inhibitor efficiently inhibited human platelet 
activation in vitro. These data provide, for the first time, proof-of-principle for a PTP-
based antiplatelet strategy using a specific small-molecule inhibitor.  
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Figure Legends 
Figure 1. Platelet activation pathways targeted by current and novel antiplatelet 
agents. 
 
Figure 2. CD148 is a critical regulator of platelet Src family kinases and platelet 
reactivity. Src family kinases (SFKs) are essential for initiating and propagating signals 
from a variety of platelet receptors, including: the low affinity immunoglobulin receptor 
FcRIIA; the von Willebrand factor (vWF) receptor complex GPIb-IX-V; the collagen 
integrin 21; the collagen activation receptor complex GPVI-FcR; the integrin IIb3, 
which binds a variety of extracellular matrix and plasma proteins including fibrinogen 
and vWF; and the podoplanin receptor CLEC-2. Dark green boxes in the cytoplasmic 
regions of FcRIIA and the FcR denote immunoreceptor tyrosine-based activation 
motifs (ITAMs); the light green box in the cytoplasmic tail of CLEC-2 denotes a hemi-
ITAM.  
 
Figure 3. PTP1B is a positive regulator of outside-in signaling from the integrin 
IIb3. Inside-out signals from various activation receptors induce the integrin IIb3 to 
undergo a conformational change from a low-affinity to a high-affinity state. C-terminal 
Src kinase (Csk), associated with the 3 subunit, maintains SFKs in an inactive state. 
Fibrinogen-mediated clustering of the high-affinity form of the intregrin triggers 
dissociation of Csk and association with PTP1B, which dephosphorylates the C-terminal 
inhibitory tyrosine residue of SFKs and initiates outside-in signaling. 
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Figure 4. Putative functions of SHP1 and SHP2 in platelets and megakaryocytes. 
(A/B) SHP1 and SHP2 have been implicated in regulating proximal signaling events 
downstream of the immunoreceptor tyrosine-based activation motif (ITAM)-containing 
collagen receptor complex GPVI-FcR, and the hemi-ITAM-containing podoplanin 
receptor CLEC-2. (C) SHP2 has also been implicated as a negative regulator of the 
integrin IIb3 in mice. It should be noted that the ITAM-containing low affinity 
immunoglobulin receptor FcγRIIA acts as a docking site for Syk downsream of IIb3 in 
human platelets, but not in mouse platelets, which do not express FcγRIIA. (D) The best-
characterized function of SHP2 in the megakaryocyte lineage is its positive regulatory 
role of the Ras-ERK1/2 pathway, downstream of the thrombopoietin (Tpo) receptor MPL. 
However, the exact mechanism remains ambiguous. Functions illustrated in this figure 
are mainly based on findings from SHP1 and SHP2 conditional knockout mice and need 
to be validated in mouse and human platelets through the use of SHP1- and SHP2-
specific inhibitors. 
 
Figure 5. VHR is a positive regulator of platelet activation in response to GPVI and 
CLEC-2 stimulation. Upon GPVI (A) and CLEC-2 (B) receptor stimulation, VHR 
positively regulates the phosphorylation of GPVI-FcR-associated ITAMs (A, dark 
green) and CLEC-2-associated hemi-ITAMs (B, light green), resulting in the recruitment 
of Syk to these receptors, and subsequent platelets activation. 
 
Figure 6. Development of a VHR-specific inhibitor. High-throughput screening (HTS) 
of the Molecular Libraries Probe Production Centers Network (MLPCN) compound 
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collection, using a colorimetric phosphatase assay with p-nitrophenyl phosphate (pNPP) 
as substrate, resulted in 1524 primary hits. Of these hits, 1048 compounds were available 
for dose-response (DR) hit confirmation assays using two orthogonal assay formats, the 
colorimetric pNPP assay, as well as a fluorimetric assay using O-methylfluorescein 
phosphate (OMFP) as substrate. 67 cross-active hits with IC50 values <20 M in both 
assays were taken into selectivity profiling experiments (SEL) against four additional 
PTPs (HePTP, STEP, LYP, and MKP-3). Based on potency and selectivity, two scaffolds 
(MLS-0103602 and MLS-0049585) were selected for structure-activity relationship 
(SAR) studies. Several analogs with similar or improved potency/selectivity could be 
identified for MLS-0049585. The four most active analogs were chosen for cell-based 
assays (CELL) and tested on human platelets freshly isolated from healthy donors. 
Compound MLS-0437605, which inhibited recombinant VHR with an IC50 of 3.7 M, 
effectively inhibited platelet aggregation at IC50 concentration, specifically in response to 
platelet stimulation with collagen-related peptide (CRP; GPVI stimulation) and 
rhodocytin (CLEC-2 stimulation), but not after stimulation with the TXA2 analog 
U46619, thereby phenocopying the effect of VHR deficiency on mouse platelets. 
Selectivity of MLS-0437605 for VHR was evaluated against a total of 10 recombinant 
PTPs, as well as under physiological conditions on VHR-deficient platelets, whose 
aggregation was only minimally affected by MLS-0437605. Finally, MLS-0437605 (3.7 
M) decreased tyrosine phosphorylation of Syk and PLC2 in human platelets in 
response to CRP and rhodocytin, similar to the effect of VHR deficiency on mouse 
platelets. (Please see Musumeci et al.
46
 to review the actual data.) 
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Table 1. Protein tyrosine phosphatases (PTPs) implicated in platelet function 
 
PTP Functions Evidence References 
CD148 
(PTPRJ) 
- positive regulator of GPVI- and CLEC-
2-mediated platelet activation, 
aggregation and IIb3-mediated 
spreading 
- positive and negative regulator of 
SFKs 
- CD148-deficient 
mouse model 
- transiently 
transfected cell line 
- in vitro biochemical 
Senis Y et al. Blood. 2009, 
113:4942-54; Ellison S et 
al. J Thromb Haemost. 
2010, 8:1575-83; Mori J et 
al. Arterioscl Thromb Vasc 
Biol. 2012, 32:2956-65 
PTP1B 
(PTPN1) 
- positive regulator of late stage platelet 
activation and aggregation 
- positive regulator of SFKs  
- implicated in dephosphorylating LAT 
- PTP1B-deficient 
mouse models 
- transiently 
transfected cell line 
- in vitro biochemical 
Frangioni JV et al. EMBO J. 
1993, 12:4843-56; Ragab A 
et al. J Biol Chem. 2003, 
278:40923-32; Arias-
Salgado EG et al. J Cell 
Biol. 2005, 170:837-45; 
Kuchay SM et al. Mol Cell 
Biol. 2007, 27:6038-52 
SHP1 
(PTPN6) 
- positive regulator of GPVI-mediated 
platelet aggregation and IIb3-
mediated spreading  
- positive regulator of SFKs 
- negative regulator of GPCR signaling 
- mediates release of RGS10 and 
RGS18 from sphinophilin 
- dephosphorylates actinin downstream 
of IIb3 
- SHP1-deficient 
mouse models 
- transiently 
transfected cell line  
- pharmacological 
(inhibitors: 
NSC87877, PTPI-1) 
- in vitro biochemical 
Pasquet JM et al. J Biol 
Chem. 2000, 275:28526-31; 
Lin SY et al. J Biol Chem. 
2004, 279:25755-64;  
Tadokoro S et al. Blood. 
2011, 117:250-8; Ma P et al. 
Blood. 2012, 119:1935-45; 
Mazharian A et al. Blood. 
2013, 121:4205-20 
SHP2 
(PTPN11) 
- negative regulator of platelet GPVI- 
and CLEC-2-mediated activation, 
aggregation and IIb3-mediated 
spreading 
- SHP2-deficient 
mouse model 
- transiently 
transfected cell line  
- in vitro biochemical 
 
Jackson DE et al. J Biol 
Chem. 1997, 272:6986-93; 
Newman DK et al. Blood. 
2001, 97:2351-7;  
Mazharian A et al. Blood. 
2013, 121:4205-20 
PTP-
MEG2 
(PTPN9) 
- biogenesis and fusion of vesicle 
membranes with the plasma 
membrane  
- PTP-MEG2-deficient 
mouse model 
 
Wang Y et al. J Exp Med. 
2005, 202:1587-97 
VHR 
(DUSP3) 
- positive regulator of GPVI- and CLEC-
2-mediated platelet activation and 
aggregation 
- VHR-deficient mouse 
model 
- pharmacological 
(inhibitor: MLS-
0437605) 
Musumeci L et al. 
Circulation. 2015, 131:656-
68 
PTEN - negative regulator of GPVI-mediated 
platelet activation and aggregation 
- PTEN-deficient 
mouse model 
Weng Z et al. Blood. 2010, 
116:2579-81 
LMPTP 
(ACP1) 
- implicated in down-regulating FcRIIA-
mediated platelet activation 
- transiently 
transfected cell line 
- in vitro biochemical 
Mancini F et al. Blood. 
2007, 110:1871-8 
 
  
Table 2. Selected pharmacological inhibitors of PTP1B and SHP2 with demonstrated 
activity in cells and/or in vivo. 
Structure/Name Potency Activity in cells Activity in vivo 
Notes and 
references 
PTP1B Inhibitors 
 
Ertiprotafib 
IC50 = 384 
nM 
Increased 
phosphorylation of 
insulin receptor 
(IR) and IR 
substrate (IRS) 1 
in 3T3-L1 
adipocytes. 
Lowered 
glucose, insulin, 
and triglycerides 
in rodent 
diabetes models. 
Progressed to 
phase II clinical 
trials for treatment 
of type 2 diabetes 
(Wyeth Research).  
Erbe D et al. Mol 
Pharmacol. 2005, 
67:69-77 
 
Trodusquemine 
IC50 = 
1,000 nM 
Increased insulin-
stimulated 
phosphorylation of 
IR in HepG2 cells 
Caused obesity-
dependent body 
weight loss. 
Lantz KA et al. 
Obesity. 2010, 
18:1516-23. 
Trodusquemine is 
an allosteric 
PTP1B inhibitor 
(Krishnan N et al. 
Nat Chem Biol. 
2014, 10:558-66). 
It was tested in 
phase I clinical 
trials for treatment 
of type 2 diabetes 
(Genaera Corp.).  
A Phase I clinical 
trial in HER2-
positive breast 
cancer patients 
is planned 
(DepYmed, Inc.). 
 
JTT-551 
Ki = 220 
nM 
Increased insulin-
stimulated glucose 
uptake in L6 cells. 
Improved 
glucose 
metabolism in 
rodents by 
enhancing insulin 
signaling. 
Fukuda S et al. 
Diabetes Obes 
Metab. 2010, 
12:299-306 
 
 
Compound II 
Ki = 26 nM 
Increased 
phosphorylation of 
IR and IRS-1, 
enhanced glucose 
uptake, Elk1 
phosphorylation, 
and cell 
proliferation, and 
activated Akt and 
ERK1/2 in 
CHO/HIRc cells. 
Restored leptin 
sensitivity in 
mature, leptin-
resistant rats. 
Xie L et al. 
Biochemistry. 
2003, 42:12792-
804 
Morrison C et al. 
Endocrinology. 
2007, 148:433-40 
 
Compound 2 
IC50 = 240 
nM 
 
Improved oral 
glucose 
tolerance and 
decreased 
plasma glucose 
and triglyceride 
levels in diet-
induced obese 
Arora SK et al. 
PCT Int Appl, WO 
2009 ⁄ 109998 
 
  
mice. 
 
Compound 5E 
IC50 = 82 
nM 
 
Caused 
reduction in body 
weight, fed-state 
whole blood 
glucose (WBG), 
fasting WBG, 
plasma glucose, 
and plasma 
cholesterol levels 
in ob/ob mice. 
Lakshminarayana 
N et al. Eur J Med 
Chem. 2010, 
45:3709-18 
 
 
Compound 3g 
IC50 = 120 
nM 
 
Inhibited glucose 
excursion in DIO 
mice. Caused a 
delay in the 
onset of tumor 
development in 
NDL2 Ptpn1 
transgenic mice. 
Han Y et al. Bioorg 
Med Chem Lett. 
2008, 18:3200-5 
 
 
Compound 79a 
IC50 = 35 
nM 
Increased 
phosphorylation of 
IR in HEK293 
cells transfected 
with plasmids 
encoding human 
IR. 
 
Combs AP et al. J 
Med Chem. 2006, 
49:3774-89 
 
SHP2 Inhibitors 
 
PHPS1 
IC50 = 
2,100 nM 
Inhibited 
hepatocyte growth 
factor/scatter 
factor (HGF/SF)-
induced epithelial 
cell scattering and 
branching 
morphogenesis. 
Blocked HGF/SF-
induced sustained 
phosphorylation of 
ERK1/2 and 
dephosphorylation 
of paxillin. Blocked 
anchorage-
independent 
growth of tumor 
cell lines. 
 
Hellmuth K et al. 
Proc Natl Acad Sci 
U S A. 2008, 
105:7275-80. 
 
 
Tautomycetin (TTN) 
IC50 = 
2,900 nM 
Blocked T cell 
receptor–
mediated ERK1/2 
activation and 
SHP2 gain-of-
function mutant-
induced 
hematopoietic 
progenitor 
hyperproliferation 
and monocytic 
differentiation. 
 
Liu S et al. Chem 
Biol. 2011, 18:101-
10. 
 
  
 
II-B08 
IC50 = 
5,500 nM 
Blocked growth 
factor stimulated 
ERK1/2 activation 
in HEK293 cells, 
and proliferation of 
GM-CSF-
stimulated bone 
marrow low 
density 
mononuclear 
cells. 
 
Zhang X et al. J 
Med Chem. 2010, 
53:2482-93 
II-B08 exhibits 
only modest (3-
fold) selectivity 
over SHP1 and 
PTP1B. 
 
NSC-87877 
IC50 = 318 
nM 
Inhibited EGF-
induced activation 
of SHP2, Ras, and 
ERK1/2 in 
HEK293 cells.  
 
Chen L et al. Mol 
Pharmacol. 2006, 
70:562-70 
NSC-87877 does 
inhibit SHP1 with a 
similar IC50 value. 
 
  
a2b1 
aIIbb3 
GPVI GPIb-IX-V 
PAR-1 
P2Y12 
TPa 
fibrinogen 
vWF 
collagen 
COX-1 TxA2 
ADP 
aspirin 
abciximab 
eptifibatide 
tirofiban 
vorapaxar 
atopaxar 
GPVI 
inhibitors 
(development) 
GPIb-IX-V/vWF 
inhibitors 
(development) 
TXA2 receptor 
antagonist 
(development) 
PDE3 
dipyridamole 
cilostazol 
clopidogrel 
prasugrel 
ticagrelor 
thrombin 
cAMP 
Amplification phase inhibitors 
Adhesion inhibitors 
Aggregation inhibitors 
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